



Paving the way to access to long-acting technologies

Moderators



Cherise Scott
Unitaid



Lobna Gaayeb
Medicines Patent Pool

With the recent signing of the first MPP long-acting technologies voluntary licence, what should we consider in order to enhance access to long-acting therapeutics for HIV prevention and treatment, and why is it critical to anticipate potential access hurdles as early as possible?

Panelists

Yves Kugbe

Long-Acting Technologies
Community Advisory Board
Reflections from the
first global community
advisory board focused on
long-acting technologies



Siobhan Crowley

The Global Fund
Determinants for
successful roll-out and
uptake



Prof. Quarraisha Abdool Karim
CAPRISA

Key considerations for
enhancing access to long-acting
technologies



Dr. N Kumarasamy

Clinton Health Access Initiative
Considerations for inclusion of
all populations throughout the
product lifecycle, including pregnant
individuals and children

Concluding remarks



Sandra Nobre
Head of Business Development
Medicines Patent Pool